265. 脂肪萎縮症 Lipodystrophy Clinical trials / Disease details
臨床試験数 : 112 / 薬物数 : 155 - (DrugBank : 55) / 標的遺伝子数 : 25 - 標的パスウェイ数 : 97
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05383456 (ClinicalTrials.gov) | April 18, 2022 | 8/4/2022 | The Visceral Adiposity Measurement and Observation Study | The Visceral Adiposity Measurement and Observation Study | HIV;HIV-Infections;HIV-1-infection;HIV I Infection;HIV Lipodystrophy;HIV Infection Primary;HIV-Associated Lipodystrophy;HIV Disease Progression;Lipohypertrophy;Liver Diseases;NAFLD;NASH;Liver Fibrosis;Hepatic Fibrosis;Waist Circumference;BMI;Ectopic Fat;Liver Fat;Hepatic Steatosis | Diagnostic Test: Diagnostic Test;Drug: HIV Anti-retroviral Background Therapy | Theratechnologies | Dacima Consulting;Medpace, Inc.;Vanderbilt University Medical Center;Echosens | Recruiting | 18 Years | N/A | All | 400 | United States |